Hu X, Ma X, Luo Y, Xu Y, Xiong Q, Pan X, Bao Y, Jia W
Department of Endocrinology and Metabolism, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai 200233, China; Shanghai Clinical Center for Diabetes, Shanghai 200233, China; Shanghai Key Clinical Center for Metabolic Disease, Shanghai 200233, China; Shanghai Diabetes Institute, Shanghai 200233, China; Shanghai Key Laboratory of Diabetes Mellitus, Shanghai 200233, China.
Department of Endocrinology and Metabolism, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai 200233, China; Shanghai Clinical Center for Diabetes, Shanghai 200233, China; Shanghai Key Clinical Center for Metabolic Disease, Shanghai 200233, China; Shanghai Diabetes Institute, Shanghai 200233, China; Shanghai Key Laboratory of Diabetes Mellitus, Shanghai 200233, China.
Nutr Metab Cardiovasc Dis. 2017 Feb;27(2):147-153. doi: 10.1016/j.numecd.2016.11.009. Epub 2016 Nov 23.
Fibroblast growth factor 23 (FGF23) was demonstrated to be involved in the occurrence and development of cardiovascular disease (CVD). The goal of the present study was to investigate the relationship between serum FGF23 levels and carotid intima-media thickness (C-IMT) in men with a low-to-moderate CVD risk.
Subjects with normal kidney function were selected from the Shanghai Obesity Study. Serum FGF23 levels were determined by sandwich enzyme-linked immunosorbent assay. C-IMT was measured by ultrasonography. The Framingham risk score (FRS) was used to assess CVD risk. A total of 392 men with low CVD risk and 372 men with moderate CVD risk were enrolled. The recognition rate of an elevated C-IMT was 85.66% with the combination of a moderate CVD risk and high serum FGF23 levels, which was greater than that with either parameter alone (65.44% and 61.03%, respectively). Subjects with high serum FGF23 levels, and either low or moderate CVD risk, were more likely to have elevated C-IMT than those with low serum FGF23 levels and low CVD risk (P = 0.014 and 0.001, respectively). The serum FGF23 levels were independently and positively associated with C-IMT in subjects with low or moderate CVD risk (both P = 0.007).
In men with low-to-moderate CVD risk, serum FGF23 levels were associated independently and positively with C-IMT. As a complementary index, serum FGF23 levels strengthen the capacity of the FRS to identify subclinical atherosclerosis.
成纤维细胞生长因子23（FGF23）被证实参与心血管疾病（CVD）的发生和发展。本研究的目的是调查心血管疾病风险较低至中等的男性血清FGF23水平与颈动脉内膜中层厚度（C-IMT）之间的关系。
从上海肥胖研究中选取肾功能正常的受试者。采用夹心酶联免疫吸附测定法测定血清FGF23水平。通过超声检查测量C-IMT。采用弗雷明汉风险评分（FRS）评估心血管疾病风险。共纳入392名心血管疾病风险较低的男性和372名心血管疾病风险中等的男性。心血管疾病风险中等且血清FGF23水平较高联合时，C-IMT升高的识别率为85.66%，高于单独使用任一参数时的识别率（分别为65.44%和61.03%）。血清FGF23水平较高且心血管疾病风险较低或中等的受试者比血清FGF23水平较低且心血管疾病风险较低的受试者更有可能出现C-IMT升高（P分别为0.014和0.001）。在心血管疾病风险较低或中等的受试者中，血清FGF23水平与C-IMT独立且呈正相关（P均为0.007）。
在心血管疾病风险较低至中等的男性中，血清FGF23水平与C-IMT独立且呈正相关。作为一个补充指标，血清FGF23水平增强了FRS识别亚临床动脉粥样硬化的能力。
